Lidocaine Hydrochloride Monohydrate, Methylprednisolone Acetate

• A Study Providing Continued Access to Treatment in Patients with a Neurological Disease Previously Enrolled in a Genentech and/or F. Hoffman… Not authorised
  2023-507633-21-00 Phase III 3 countries F. Hoffmann-La Roche AG
• Stroke in childhood due to inflammatory narrowing of blood vessels: Treatment with steroids Pending
  2022-500631-36-00 Phase III 5 countries Insel Gruppe AG
• ATA-200 gene therapy trial in patients with LGMDR5 Pending
  2023-506440-16-00 Phase I (FiH) 2 countries Atamyo Therapeutics
• Utility of the use of N-acetylcisteine associated with conventional treatment in patients with severe acute alcoholic hepatitis (Maddrey>=32… Pending
  2023-510163-35-00 Phase III 1 country Asociacion Instituto De Investigacion Sanitaria Bioaraba
• Severe Erythema Multiforme - CORTICO Pending
  2024-516018-39-00 Phase III 1 country Assistance Publique Hopitaux De Paris
• HiHat trial Pending
  2024-519700-28-01 Phase II 1 country Region Uppsala
• Framework for Optimizing, Refining, and Unifying Management of HSCT in Pediatric ALL. Recruiting
  2025-522052-13-00 Phase II/III 9 countries Ospedale Pediatrico Bambino Gesu
• A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN) ( PREVAIL ) Recruiting
  2024-519345-30-00 Phase III 11 countries Biogen Idec Research Limited
• Reduced Immunosuppression for Older Adult Kidney Transplant Recipients: the RELEASE study. Recruiting
  2025-520535-16-00 Phase IV 1 country Consorci Mar Parc De Salut De Barcelona
• Efficacy of methylprednisolone pulses in neuroendocrine cells hyperplasia of infancy: an early phase study (CORTICONEHI). Recruiting
  2023-508132-65-00 Phase II 1 country Assistance Publique Hopitaux De Paris
• Efficacy and safety trial of GNT0003 following imlifidase pre-treatment in participants aged 16 years and older with severe Crigler-Najjar s… Recruiting
  2023-510405-18-00 Phase II 1 country Genethon
• JAKAHDI - JAK inhibitors in acquired hemophagocytic syndrome in the ICU Recruiting
  2023-504513-77-00 Phase II 1 country Assistance Publique Hopitaux De Paris
• Study of efficacy and safety of LNP023 in participants with active lupus nephritis Class III-IV, +/- V Recruiting
  2023-509332-26-00 Phase II 5 countries Novartis Pharma AG
• Gene Therapy for Crigler-Najjar Syndrome Recruiting
  2023-507007-60-00 Phase I (FiH) 3 countries Genethon
• Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer Ended
  2024-512998-27-00 Phase III 15 countries Genmab A/S
• International treatment-extension study in adult participants with multiple myeloma and who have derived clinical benefit from isatuximab Ended
  2023-507180-19-00 Phase II 7 countries Sanofi-Aventis Recherche & Developpement
• A study to investigate subcutaneous isatuximab in combination with carfilzomib and dexamethasone in adult participants with relapsed and/or … Ended
  2023-508870-27-00 Phase II 3 countries Sanofi-Aventis Recherche & Developpement
• ATA-100 gene therapy trial in patients with limb-girdle muscular dystrophy Ended
  2023-506677-36-00 Phase I (FiH) 2 countries Atamyo Therapeutics
• A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Patients with ISN/RPS 2003 Class III or IV Lupus Nephritis Ended
  2023-503628-22-00 Phase III 5 countries F. Hoffmann-La Roche AG
• Isatuximab in combination with lenalidomide and dexamethasone in high-risk smoldering multiple myeloma Ended
  2023-507419-37-00 Phase III 11 countries Sanofi-Aventis Recherche & Developpement
• A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults with Primary Progressive Multiple Sclerosis Ended
  2023-505980-36-00 Phase III 9 countries F. Hoffmann-La Roche AG
• Evaluate the Safety, Efficacy, and Pharmacokinetics of CRN04894 in Participants with Congenital Adrenal Hyperplasia Ended
  2023-503488-40-00 Phase II 2 countries Crinetics Pharmaceuticals Inc.
• A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma Ended
  2023-505169-10-00 Phase II 1 country Kite Pharma Inc.

Showing 1–23 of 23 trials